Contrasting Celcuity (CELC) & Its Peers
Celcuity (NASDAQ: CELC) is one of 23 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Celcuity to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
15.2% of Celcuity shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by insiders. Comparatively, 16.6% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Celcuity and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||443.52|
Celcuity’s competitors have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Celcuity and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Celcuity and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity currently has a consensus price target of $35.50, indicating a potential upside of 51.72%. As a group, “Medical laboratories” companies have a potential upside of 17.08%. Given Celcuity’s stronger consensus rating and higher probable upside, equities analysts clearly believe Celcuity is more favorable than its competitors.
Volatility & Risk
Celcuity has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s competitors have a beta of 1.33, suggesting that their average stock price is 33% more volatile than the S&P 500.
Celcuity beats its competitors on 7 of the 13 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.